INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Under the Paperwork Reduction Act of 1995, no persons are required

	Application Number		10791194			
	Filing Date		2004-03-02			
First Named Inventor Frank		Frank	L Hall			
	Art Unit		1725			
Examiner Name S. He		S. He	inrich			
	Attorney Docket Numb	er	2269-4718.2US(00-0316.02/			

			U.S.PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
	1	4586822		1986-05-06	Tanimoto			
	2	4780177		1988-10-25	Wojnarowski et al.			
	3	6507497	B2	2003-01-14	Mashino			
	4	6608259	B1	2003-08-19	Norskov			
	5	6610548	B1	2003-08-26	Ami et al.			
	6	6617681	B1	2003-09-09	Bohr			
	7	6917011	B2	2005-07-12	Hong et al.			
If you wis	h to a	dd additional U.S. Pa	tent citatio	n information p	lease click the Add button.	Add		

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

pplication Number		10791194		
iling Date		2004-03-02		
irst Named Inventor Frank		L. Hall		
rt Unit		1725		
xaminer Name S. He		inrich		
ttorney Docket Number		2269-4718.2US(00-0316.02/		

Date Considered

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ation	Name of Patentee or Applicant Relev		es,Columns,Lines where evant Passages or Releve res Appear			
	1	20030086248	A1	2003-05-08 Mashino							
If you wisl	h to a	dd additional U.S. Publ	shed Ap	plication	citatio	n information p	please click the Ad	d butto	n. Add		
				FORE	GN PAT	TENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>			Kind Publication Name of Patentee or Applicant of cited Passage		where Re	or Relevant	TS	
	1										
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information p	lease click the Add	button	Add		
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner linitials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sorial, symposium, catabg, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					Ţŝ						
	1										

A

E

FXAMINER SIGNATURE \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you wish to add additional non-patent literature document citation information please click the Add button Add

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached

Examiner Signature

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 GFR 1.99)

Application Number		10791194		
Filing Date		2004-03-02		
First Named Inventor Frank		L. Hall		
Art Unit		1725		
Examiner Name S. He		inrich		
Attorney Docket Numb	er	2269-4718.2US(00-0316.02/		

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	7 and 1.98 to	make the	appropriate	selection(s	s):	
---------------	----------	---------------	----------	-------------	-------------	-----	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a deeping patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to a not individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- \_ ...

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/James R. Duzan/	Date (YYYY-MM-DD)	2007-06-11
Name/Print	James R. Duzan	Registration Number	28393

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the process of the process and the process of the pro

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these cords.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.